Lixte Biotechnology (LIXT) 10-K 21 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 11, 2022	Jun. 30, 2021
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-51476
Entity Registrant Name	LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	0001335105
Entity Tax Identification Number	20-2903526
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	680 East Colorado Boulevard
Entity Address, Address Line Two	Suite 180
Entity Address, City or Town	Pasadena
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91101
City Area Code	631
Local Phone Number	830-7092
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 30,550,000
Entity Common Stock, Shares Outstanding		13,746,593
ICFR Auditor Attestation Flag	false
Auditor Firm ID	572
Auditor Name	Weinberg & Company, P.A
Auditor Location	Los Angeles, California
Common Stock [Member]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	LIXT
Security Exchange Name	NASDAQ
Warrant [Member]
Title of 12(b) Security	Warrants to Purchase Common Stock, par value $0.0001 per share
Trading Symbol	LIXTW
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 4,823,745	$ 5,069,266
Advances on research and development contract services	150,241	76,898
Prepaid insurance	109,029	67,311
Other prepaid expenses and current assets	10,249	15,000
Total current assets	5,093,264	5,228,475
Total assets	5,093,264	5,228,475
Current liabilities:
Accounts payable and accrued expenses, including $32,500 and $0 to related parties at December 31, 2021 and 2020, respectively	225,965	190,292
Accrued offering costs		10,467
Research and development contract liabilities	76,961	15,765
Total current liabilities	302,926	216,524
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 729,167 shares	3,500,000	3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 13,746,593 shares and 12,402,157 shares at December 31, 2021 and 2020, respectively	1,374	1,240
Additional paid-in capital	38,371,128	31,864,479
Accumulated deficit	(37,082,164)	(30,353,768)
Total stockholders’ equity	4,790,338	5,011,951
Total liabilities and stockholders’ equity	$ 5,093,264	$ 5,228,475

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accounts payable and accrued expenses	$ 32,500	$ 0
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,746,593	12,402,157
Common stock, shares outstanding	13,746,593	12,402,157
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 10	$ 10
Preferred stock, shares issued	350,000	350,000
Preferred stock, shares outstanding	350,000	350,000
Preferred stock, issuable upon conversion	729,167	729,167

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues
General and administrative costs:
Compensation to related parties, including stock-based compensation of $2,201,280 and $480,634 for the years ended December 31, 2021 and 2020, respectively	2,931,280	765,085
Patent and licensing legal and filing fees and costs	729,171	553,173
Other	1,323,218	724,506
Research and development costs, including $397,642 and $670,715 of stock-based compensation costs to a consultant for the years ended December 31, 2021 and 2020, respectively	1,736,776	1,223,676
Total costs and expenses	6,720,445	3,266,440
Loss from operations	(6,720,445)	(3,266,440)
Interest income	626	4,342
Interest expense	(7,414)	(3,674)
Foreign currency gain (loss)	(1,163)	890
Net loss	$ (6,728,396)	$ (3,264,882)
Net loss per common share – basic and diluted	$ (0.50)	$ (0.29)
Weighted average common shares outstanding – basic and diluted	13,473,839	11,277,126

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Allocated share based, compensation expense	$ 2,201,280	$ 480,634
Consultant [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Allocated share based, compensation expense	$ 397,642	$ 670,715

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Series A Convertible Preferred Stock [Member]Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2019	$ 3,500,000	$ 1,117	$ 26,021,904	$ (27,088,886)	$ 2,434,135
Balance, shares at Dec. 31, 2019	350,000	11,174,737
Proceeds from sale of common stock units in public offering, net of offering costs		$ 120	4,591,229		$ 4,591,349
Proceeds from sale of common stock units in public offering, net of offering costs, shares		1,200,000
Exercise of options, shares
Stock-based compensation expense			1,151,349		$ 1,151,349
Common stock issued for services		$ 3	99,997		100,000
Common stock issued for services, shares		27,420
Net loss				(3,264,882)	(3,264,882)
Balance at Dec. 31, 2020	$ 3,500,000	$ 1,240	31,864,479	(30,353,768)	5,011,951
Balance, shares at Dec. 31, 2020	350,000	12,402,157
Proceeds from sale of common stock in direct equity offering, net of offering costs		$ 113	3,689,648		3,689,761
Proceeds from sale of common stock in direct equity offering, net of offering costs, shares		1,133,102
Exercise of warrants		$ 1	17,099		17,100
Exercise of warrants, shares		3,000
Exercise of options		$ 20	200,980		$ 201,000
Exercise of options, shares		208,334			208,334
Stock-based compensation expense			2,598,922		$ 2,598,922
Net loss				(6,728,396)	(6,728,396)
Balance at Dec. 31, 2021	$ 3,500,000	$ 1,374	$ 38,371,128	$ (37,082,164)	$ 4,790,338
Balance, shares at Dec. 31, 2021	350,000	13,746,593

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2020USD ($)
Statement of Stockholders' Equity [Abstract]
Extension of stock options	$ 670,715

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (6,728,396)	$ (3,264,882)
Stock-based compensation expense included in -
General and administrative costs	2,201,280	580,634
Research and development costs	397,642	670,715
(Increase) decrease in -
Advances on research and development contract services	(73,343)	(76,898)
Accrued interest receivable		14,367
Prepaid insurance	(41,718)	(32,803)
Other prepaid expenses and current assets	4,751	9,294
Accounts payable and accrued expenses	35,673	46,743
Research and development contract liabilities	61,196	(78,584)
Net cash used in operating activities	(4,142,915)	(2,131,414)
Cash flows from financing activities:
Proceeds from sale of common stock units in public offering, net of offering costs		4,601,816
Proceeds from sale of common stock in direct equity offering, net of offering costs	3,689,761
Exercise of common stock warrants	17,100
Exercise of common stock options	201,000
Payment of costs incurred in connection with sale of common stock units	(10,467)
Net cash provided by financing activities	3,897,394	4,601,816
Cash:
Net increase (decrease)	(245,521)	2,470,402
Balance at beginning of period	5,069,266	2,598,864
Balance at end of period	4,823,745	5,069,266
Supplemental disclosures of cash flow information:
Interest	7,414	3,674
Income taxes
Non-cash investing and financing activities:
Accrued offering costs (paid subsequent to December 31, 2020)		$ 10,467

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Lixte Biotechnology Holdings, Inc., a Delaware corporation (“Holdings”), including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (“Lixte”) (collectively, the “Company”), is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The Company has developed two classes of drugs for the treatment of cancer, consisting of protein phosphatase inhibitors (PTase-i), designated by us as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by us as the LB-200 series of compounds. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its operating requirements. The Company’s common stock and the warrants issued in the public offering (see Note 3) are traded on The Nasdaq Capital Market under the symbols “LIXT” and. “LIXTW”, respectively. Going Concern At December 31, 2021, the Company had cash of $ 4,823,745 The Company’s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements primarily through the recurring sale of its equity securities. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, 2021, has also expressed substantial doubt about the Company’s ability to continue as a going concern. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future cash requirements depends on the pace and design of the Company’s clinical trial program, which, in turn, depends on the availability of operating capital to fund such activities. Based on current operating plans, the Company estimates that it will need to raise additional capital to fund its operations, including its various clinical trial commitments, during the quarter ending September 30, 2022. In addition, the Company’s operating plans may change as a result of many factors which are currently unknown to the Company, including possible additional clinical trials, and the Company may need additional funds sooner than currently planned. As market conditions present uncertainty as to the Company’s ability to secure additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations. There is also significant uncertainty as to the effect that the coronavirus pandemic may have on the Company’s clinical trial schedule and the amount and type of financing available to the Company in the future. If cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights to and/or control of LB-100, or to discontinue operations entirely. Reverse Stock Split On November 18, 2020, the Company effected a 1-for-6 reverse All share and per share amounts and information presented herein has been retroactively adjusted to reflect the reverse stock split for all periods presented.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Holdings and its wholly owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments issued for services, and the realization of deferred tax assets. Cash Cash is primarily held in a cash bank deposit program maintained by a major financial institution. The Company’s policy is to maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the “FDIC”) and/or by the Securities Investor Protection Corporation (the “SIPC”). The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $ 250,000 500,000 Research and Development Research and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the acquisition, design, development and clinical trials with respect to the Company’s compounds and product candidates. Research and development costs also include the costs to produce the compounds used in research and clinical trials, which are charged to operations as incurred. Research and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are charged to operations as incurred. Obligations incurred with respect to mandatory scheduled payments under research agreements with milestone provisions are recognized as charges to research and development costs in the Company’s consolidated statement of operations based on the achievement of such milestones, as specified in the agreement. Obligations incurred with respect to mandatory scheduled payments under research agreements without milestone provisions are accounted for when due, are recognized ratably over the appropriate period, as specified in the agreement, and are recorded as liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet and are then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis. Prepaid Insurance Prepaid insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amortization is determined by amortizing the total policy premium charged on a straight-line basis over the respective policy periods. As the policy premiums incurred are amortizable in the ensuing twelve-month period, they are recorded as a current asset in the Company’s consolidated balance sheet at each reporting date and amortized to the Company’s consolidated statement of operations for each reporting period. Patent and Licensing Legal and Filing Fees and Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development and protection of its intellectual property are charged to operations as incurred. Patent and licensing legal and filing fees and costs were $ 729,171 553,173 Concentration of Risk The Company periodically contracts with vendors and consultants to provide services related to the Company’s operations. Charges incurred for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred that represented 10 General and administrative costs for the years ended December 31, 2021 and 2020 include combined charges from two legal firms for general licensing and patent prosecution costs relating to the Company’s intellectual properties representing 14.6 27.1 44.2 23.5 Research and development costs for the year ended December 31, 2021 include charges from three vendors and consultants representing 30.3 21.8 14.4 65.6 13.7 Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no 12 The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2021 or 2020. Subsequent to December 31, 2021, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. Stock-Based Compensation The Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period. The Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members contractors and consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between the vesting period and the contractual term (the “simplified method”). The estimated volatility is based on the historical volatility of the Company’s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of the common stock is determined by reference to the quoted market price of the Company’s common stock on the grant date. The expected dividend yield is based on the Company’s expectation of dividend payouts and is assumed to be zero. The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option exercises. Earnings (Loss) Per Share The Company’s computation of earnings (loss) per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options outstanding were anti-dilutive. At December 31, 2021 and 2020, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 December 31, 2021 2020 Series A Convertible Preferred Stock 729,167 729,167 Common stock warrants 3,110,310 3,000,000 Common stock options, including options issued in the form of warrants 2,666,667 1,475,000 Total 6,506,144 5,204,167 Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives and commingled investment funds and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments. Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions and enhances and simplifies various aspects of the income tax accounting guidance in ASC 740. The Company adopted ASU 2019-12 effective January 1, 2021. The adoption of ASU 2019-12 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. In August 2020, the FASB issued ASU 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon adoption of ASU 2020-06, convertible debt proceeds, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For contracts in an entity’s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company adopted ASU 2020-06 effective January 1, 2021. The adoption of ASU 2020-06 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The adoption of ASU 2021-04 is not expected to have any impact on the Company’s consolidated financial statement presentation or disclosures. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders’ Equity	3. Stockholders’ Equity Preferred Stock The Company is authorized to issue a total of 10,000,000 0.0001 350,000 175,000 1 175,000 9,650,000 Each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 2.0833 21,875,000 If fully converted, the 350,000 729,167 50.00 175,000 Based on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible Preferred Stock as a permanent component of stockholders’ equity. Common Stock The Company is authorized to issue a total of 100,000,000 0.0001 13,746,593 12,402,157 Effective November 30, 2020, the Company raised gross proceeds of $ 5,700,000 1,200,000 4.75 5.70 1,800 180,000 5.70 1,110,451 4,591,349 120,000 May 24, 2021 5.70 Effective December 21, 2020, the Company entered into a one-year services agreement with IRTH Communications, LLC for investor/public relations, financial communications, and strategic consulting services. The services agreement provided for the issuance of restricted shares of common stock, fully vested upon issuance, with a grant date fair value of $ 100,000 27,420 3.65 During February and March 2021, the Company issued 3,000 3,000 5.70 17,100 Effective March 2, 2021, the Company completed the sale of 1,133,102 3.70 4,192,478 502,717 3,689,761 113,310 3.70 Effective April 22, 2021, stock options held by an officer and two of the Company’s directors for 125,001 75,000 0.72 16,667 0.90 33,334 0.96 101,000 125,001 Effective July 14, 2021, a stock option held by a consultant of the Company for 83,333 1.20 100,000 83,333 Common Stock Warrants A summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s public offering, during the years ended December 31, 2021 and 2020 is presented below. Schedule of Warrants Outstanding Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2019 1,500,000 $ 6.000 Issued 1,500,000 5.700 Exercised — — Expired — — Warrants outstanding at December 31, 2020 3,000,000 $ 5.850 Issued 113,310 3.700 Exercised (3,000 ) 5.700 Expired — — Warrants outstanding at December 31, 2021 3,110,310 $ 5.772 2.48 Warrants exercisable at December 31, 2020 3,000,000 $ 5.850 Warrants exercisable at December 31, 2021 3,110,310 $ 5.772 2.48 At December 31, 2021, the outstanding warrants are exercisable at the following prices per common share: Schedule of Warrants Outstanding and Exercisable Exercise Prices Warrants Outstanding (Shares) $ 3.700 113,310 $ 5.700 1,497,000 $ 6.000 1,500,000 3,110,310 Based on a fair market value of $ 1.19 Information with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 5.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	4. Related Party Transactions Related party transactions include transactions with the Company’s officers, directors and affiliates. Gil N Schwartzberg On September 12, 2007, the Company entered into a consulting agreement with Gil N Schwartzberg for Mr. Schwartzberg to provide financial advisory and consulting services to the Company with respect to financing matters, capital structure and strategic development, and to assist management in communications with investors and stockholders. Mr. Schwartzberg is currently a significant stockholder and director of the Company. Consideration under this consulting agreement, including amendments thereto, has been paid exclusively in the form of stock options. On August 2, 2018, the Company entered into a third amendment to the consulting agreement to extend it to January 28, 2024, as well as to extend the exercise date of previously issued, fully-vested stock options for 666,667 3.00 Employment Agreements with Officers During July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. The employment agreements are automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically renewed for an additional one-year period in July and August 2021. The Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, for Dr. Kovach to continue to act as the Company’s President, Chief Executive Officer and Chief Scientific Officer with an annual salary of $ 250,000 250,000 62,500 45,000 The Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020 to act as the Company’s Chief Medical Officer with an annual salary of $ 150,000 175,000 166,667 62,500 The Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the Company’s Chief Administrative Officer with an annual salary of $ 120,000 175,000 156,667 30,000 38,000 The Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company’s Vice President and Chief Financial Officer with an annual salary of $ 120,000 175,000 156,667 46,451 79,995 Compensatory Arrangements for Board of Directors Effective April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation package for the members of the Board of Directors and committee members. The Board of Directors approved the following cash compensation for non-officer independent directors, payable quarterly: Base director compensation - $ 20,000 Chairman of audit committee - additional $ 10,000 Chairman of any other committees - additional $ 5,000 Member of audit committee - additional $ 5,000 Member of any other committees - additional $ 2,500 Total cash compensation paid to independent directors was $ 92,833 Stock-based compensation arrangements involving members of the Company’s Board of Directors. officers and affiliates are described at Note 5. A summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors for their services on the Board of Directors, for the years ended December 31, 2021 and 2020 is presented below. This summary includes the above-described payments to Mr. Forman in 2020 prior to his appointment as Chief Administrative Officer and excludes the payments to Mr. Weingarten in 2020 prior to his appointment as Vice President and Chief Financial Officer. Summary of Related Party Costs 2021 2020 Years Ended December 31, 2021 2020 Related party costs: Cash-based $ 822,834 $ 284,451 Stock-based 2,201,280 480,634 Total $ 3,024,114 $ 765,085

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	5. Stock-Based Compensation The Company issues common stock and stock options as incentive compensation to directors and as compensation for the services of employees, contractors, and consultants of the Company. On July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which provides for the granting of equity-based awards, consisting of stock options, restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and consultants of the Company and its affiliates for up to 2,333,333 1,400,000 933,333 Effective April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation package for the members of the Board of Directors and committee members. Cash-based features of the compensation package are described at Notes 4 and 7. Stock-based features of the compensation package consisted of the annual granting of stock options to each non-officer director to purchase 100,000 the granting of stock options to a new director to purchase 250,000 The fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the Company’s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility of the Company’s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between the vesting period and the contractual term (the “simplified method”). The fair market value of the common stock is determined by reference to the quoted market price of the common stock on the grant date. For stock options requiring an assessment of value during the year ended December 31, 2021, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions: Schedule of Fair Value of Each Option Award Estimated Assumption Risk-free interest rate 0.89 1.13 % Expected dividend yield 0 % Expected volatility 187.7 198.8 % Expected life 3.5 5 For stock options requiring an assessment of value during the year ended December 31, 2020, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions: Risk-free interest rate 0.23 0.31 % Expected dividend yield 0 % Expected volatility 207.7 % Expected life 4 5 Effective September 14, 2015, in connection with the Collaboration Agreement with BioPharmaWorks LLC (“BioPharmaWorks”) as described at Note 7, the Company issued to BioPharmaWorks two stock options, in the form of warrants, to purchase 166,667 83,333.5 five years 6.00 five years 12.00 166,667 September 14, 2020 to September 14, 2025 5.40 670,715 4.0242 On July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman was granted options for 58,333 five years 7.14 400,855 6.8718 100,214 100,213 138,926 On August 1, 2020, in connection with an employment agreement entered into with Dr. James S. Miser, M.D., Dr. Miser was granted options for 83,334 five years 7.14 572,650 6.8718 143,163 143,163 202,782 On August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted options for 58,333 five years 7.14 400,855 6.8718 100,214 100,213 138,926 Effective January 6, 2021, in recognition of their service as directors of the Company over the past year, the Company granted fully-vested stock options to purchase 50,000 200,000 five years 3.21 571,312 2.8566 On April 9, 2021, Winson Sze Chun Ho resigned from the Company’s Board of Directors to focus on clinical and pre-clinical cancer research in academic medicine. Concurrent with his resignation, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by Dr. Ho’s resignation. In connection with his appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Schwartzberg was granted options exercisable for a period of five years 250,000 3.20 753,611 3.0144 376,800 500,235 On May 11, 2021, the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Ms. Brown was granted options exercisable for a period of five years 250,000 2.80 658,363 2.6335 329,188 427,944 On June 30, 2021, the Board of Directors, in accordance with the recently adopted cash and equity compensation package for the members of the Board of Directors, granted to each of the five non-officer directors of the Company stock options exercisable for a period of five years 100,000 500,000 3.03 500,000 1,421,095 2.84225 358,200 On November 8, 2021, the Company issued to BioPharmaWorks a stock option, in the form of a warrant, to purchase 200,000 five years 2.06 397,642 1.9882 A summary of stock-based compensation costs for the years ended December 31, 2021 and 2020 is as follows: Summary of Stock-based Compensation Costs 2021 2020 Years Ended December 31, 2021 2020 Related parties $ 2,201,280 $ 480,634 Non-related parties 397,642 770,715 Total stock-based compensation costs $ 2,598,922 $ 1,251,349 A summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2021 and 2020 is presented below. Summary of Stock Option Activity Including Options Form of Warrants Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Stock options outstanding at December 31, 2019 1,308,333 $ 3.648 Granted 200,000 7.140 Exercised — — Expired (33,333 ) 3.000 Rounding adjustment attributable to reverse stock split Weighted average exercise price, reverse stock split Stock options outstanding at December 31, 2020 1,475,000 4.136 Granted 1,400,000 2.906 Exercised (208,334 ) 0.965 Expired — — Rounding adjustment attributable to reverse stock split 1 — Stock options outstanding at December 31, 2021 2,666,667 $ 3.738 3.42 Stock options exercisable at December 31, 2020 1,325,000 $ 3.796 Stock options exercisable at December 31, 2021 2,004,167 $ 3.770 3.13 Total deferred compensation expense for the outstanding value of unvested stock options was approximately $ 2,097,000 18 The exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at December 31, 2021 are as follows: Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants Exercise Prices Options Outstanding Options Exercisable $ 0.900 33,333 33,333 $ 1.680 66,667 66,667 $ 2.060 200,000 200,000 $ 2.800 250,000 156,250 $ 3.000 666,667 666,667 $ 3.030 500,000 125,000 $ 3.200 250,000 156,250 $ 3.210 200,000 200,000 $ 6.000 166,667 166,667 $ 6.600 50,000 50,000 $ 7.140 200,000 100,000 $ 12.000 83,333 83,333 2,666,667 2,004,167 The intrinsic value of exercisable but unexercised in-the-money stock options at December 31, 2021 was approximately $ 10,000 1.19 Outstanding stock options to acquire 662,500 The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets as of December 31, 2021 and 2020 are summarized below. Schedule of Components of Deferred Tax Assets 2021 2020 December 31, 2021 2020 Start-up and organization costs $ — $ 5,000 Research credits 451,000 390,000 Stock-based compensation 1,821,000 1,107,000 Net operating loss carryforwards 6,723,000 5,477,000 Total deferred tax assets 8,995,000 6,979,000 Valuation allowance (8,995,000 ) (6,979,000 ) Net deferred tax assets $ — $ — In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2021 and 2020, management was unable to determine if it is more likely than not that the Company’s deferred tax assets will be realized and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates. No Schedule of Effective Income Tax Rate 2021 2020 Years Ended December 31, 2021 2020 U. S. federal statutory tax rate (21.0 )% (21.0 )% State income taxes, net of federal tax benefit (6.0 )% (6.0 )% Expirations related to stock-based compensation 0.6 % 0.5 % Adjustment to deferred tax asset (0.4 )% (0.8 )% Change in valuation allowance 26.8 % 27.3 % Effective tax rate 0.0 % 0.0 % At December 31, 2021, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately $ 23,173,000 23,287,000 expire through 2041 19,141,000 The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $ 928,313 4,146,000

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Legal Claims The Company may be subject to legal claims and actions from time to time as part of its business activities. As of December 31, 2021, the Company was not subject to any pending or threatened legal claims or actions. Principal Commitments Clinical Trial Agreements At December 31, 2021, the Company’s contractual commitments pursuant to clinical trial agreements, clinical trial monitoring agreements, and agreements for the production of LB-100 for clinical use, as described below, aggregated $ 8,646,000 Moffitt. In November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application (“IND”) to conduct a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of LB-100 in patients with low and intermediate-1 risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally well except for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilizes LB-100 as a single agent in the treatment of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line therapy. The bone marrow cells of patients with del5qMDS are deficient in PP2A by virtue of an acquired mutation and are especially vulnerable to further inhibition of PP2A by LB-100. The clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. A total enrollment of 41 patients is planned. An interim analysis will be done after the first 21 patients are entered. If there are 3 or more responders but fewer than 7, an additional 20 patients will be entered. If at any point there are 7 or more responders, this will be sufficient evidence to support continued development of LB-100 for the treatment of low and intermediate-1 risk MDS. Recruitment has been slow and the Covid-19 pandemic has further reduced recruitment of patients into the protocol. At the current rate of accrual, the clinical trial is expected to be completed by June 30, 2025. However, with additional funds, the Company would consider adding two additional MDS centers to the Phase 2 portion of the study to accelerate patient accrual. During the years ended December 31, 2021 and 2020, the Company incurred costs of $ 18,443 41,142 104,677 The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $ 601,000 GEIS. GEIS has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as well as to provide funding for the clinical trial. The goal was to enter approximately 150 patients in this clinical trial over a period of two years. As advanced sarcoma is a very aggressive disease, the design of the study assumes a median progression free survival (PFS, no evidence of disease progression or death from any cause) of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required for final analysis is reached. The Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July 2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol, it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These standards were adopted subsequent to the production of the Company’s existing LB-100 inventory. A new batch of LB 100 has been prepared and is now undergoing the multitude of analytical studies of the formulated product necessary to gain approval for use in the European Union. Regulatory reviews by the European Union have been delayed, as a result of which the final review of the clinical product by Spanish regulatory authorities will also be delayed. Accordingly, the clinical trial is now estimated to begin during the quarter ending June 30, 2022 and be completed by June 30, 2025. The interim analysis of this clinical trial could indicate either inferiority or superiority of LB-100 plus doxorubicin as compared to doxorubicin alone. A positive study would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit of doxorubicin alone. The Company’s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement. Through December 31, 2021, the Company has paid GEIS an aggregate of $ 67,582 During the years ended December 31, 2021 and 2020, the Company incurred costs of $ 24,171 43,411 155,053 The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $ 4,250,000 In order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company has engaged a number of vendors to carry out the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks include the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the steps involved by an independent auditor. The API is then transferred to a vendor that prepares the clinical drug product, also under GMP conditions documented by an independent auditor. The clinical drug product is then sent to a vendor to test for purity and sterility, provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal application documenting all steps taken to prepare the clinical drug product for clinical use must be submitted to the appropriate regulatory authorities for review and approval before being used in a clinical trial. On November 2, 2021, the Company entered into a Development Agreement with Famar Health Care Services Madrid SA (“Famar”) to prepare a new batch of clinical LB-100 for use in clinical trials to be conducted in the European Union. During the year ended December 31, 2021, the Company incurred costs of $ 119,860 The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $ 180,000 As of December 31, 2021, the Company estimates that this program to provide new inventory of the clinical drug product for the Spanish sarcoma study, and potentially for subsequent multiple trials within the European Union, including the costs incurred and to be incurred with Famar as described above, will cost approximately $ 1,076,000 318,000 City of Hope. The clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. If LB-100 does potentiate the benefit of the standard regimen, some evidence could be noted at 12 months into the clinical trial, but an assessment of potential increased activity is likely to require at least 24 months. The Company is currently seeking to add two additional centers to increase the rate of accrual. The Company expects this clinical trial to be completed by June 30, 2024. During the year ended December 31, 2021, the Company incurred costs, and total costs, of $ 378,511 2,433,000 800,000 National Cancer Institute Pharmacologic Clinical Trial. Primary malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with some further benefit gained by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal models of GBM, the Company’s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation, temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain is not known. Unfortunately, many drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action. The NCI study is designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove one or more tumors will receive one dose of LB-100 prior to surgery and have blood and tumor tissue analyzed to determine the amount of LB-100 present and to determine whether the cells in the tumors show the biochemical changes expected to be present if LB-100 reaches its molecular target. The goal is to obtain data in up to eight patients. As a result of the innovative design of the NCI study, data from so few patients should be sufficient to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment regimen for GBMs. The neurosurgical unit at the NCI, which had been closed due to the Covid-19 epidemic, has reopened, and patient accrual has resumed. Patient entry remains at two, with the goal to enter eight patients before analyzing results. There is an urgent need to improve therapy for this type of aggressive brain tumor. If the NCI study shows that LB-100 does penetrate the brain, a clinical study of LB-100 in combination with standard therapy for GBM, the drug temozolomide and radiation, both of which have been well documented in pre-clinical studies to be significantly enhanced by LB-100, would be of significant interest to neuro-oncologists frustrated by decades of limited advances in therapy for this common brain tumor in adults. Clinical Trial Monitoring Agreements Moffitt. Costs under this work order agreement are estimated to be approximately $ 954,000 9,750 18,663 91,885 868,000 City of Hope. 24,626 24,626 314,000 Patent and License Agreements On March 22, 2018, the Company entered into a Patent Assignment and Exploitation Agreement with INSERM TRANSFERT SA, acting as delegatee of the French National Institute of Health and Medical Research, for the assignment to the Company of INSERM’S interest in United States Patent No. 9,833,450 entitled “Oxabicyloheptanes and Oxabicycloheptenes for the Treatment of Depressive and Stress Disorders”, which was filed with the United States Patent and Trademark Office in the name of INSERM and the Company as co-owners on February 19, 2015 and granted on May 12, 2017, and related patent applications and filings. INSERM is a French public institution dedicated to research in the field of health and medicine that had previously entered into a Material Transfer Agreement with the Company to allow INSERM to conduct research on the Company’s proprietary compound LB-100 and/or its analogs for the treatment of depressive or stress disorders in humans. Pursuant to the Agreement, the Company has agreed to make certain milestone payments to INSERM aggregating up to $ 1,750,000 6,500,000 no Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement, Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the “Licensed Patents”) relating to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results, clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $ 25,000 25,000 1,897,000 24,999 25,001 The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $ 50,000 100,000 Employment Agreements with Officers During July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual compensation of $ 640,000 one-year period On April 9, 2021, the Board of Directors increased the annual compensation of Eric J. Forman, the Company’s Chief Administrative Officer, Dr. James S. Miser, the Company’s Chief Medical Officer, and Robert N. Weingarten, the Company’s Chief Financial Officer, under the employment agreements such that the total aggregate annual compensation of all officers increased to $ 775,000 Other Significant Agreements and Contracts On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company’s Scientific Advisory Committee. The term of the agreement was for one year and provided for a quarterly cash fee of $ 4,000 16,000 16,000 Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged BioPharmaWorks to perform certain services for the Company. Those services included, among other things: (a) assisting the Company to (i) commercialize its products and strengthen its patent portfolio, (ii) identify large pharmaceutical companies with potential interest in the Company’s product pipeline, and (iii) prepare and deliver presentations concerning the Company’s products; (b) at the request of the Board of Directors, serving as backup management for up to three months should the Company’s Chief Executive Officer and scientific leader be temporarily unable to carry out his duties; (c) being available for consultation in drug discovery and development; and (d) identifying providers and overseeing tasks relating to clinical use and commercialization of new compounds. BioPharmaWorks was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience. The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the Company agreed to pay BioPharmaWorks a monthly fee of $ 10,000 120,000 120,000 Effective August 12, 2020, the Company entered into a Master Service Agreement with the Foundation for Angelman Syndrome Therapy (FAST) to collaborate in supporting pre-clinical studies of the potential benefit of LB-100 in a mouse model of Angelman Syndrome (AS) as reported in The Proceedings of The National Academy of Science (Wang et al, June 3, 2019). The pre-clinical studies will be conducted at The University of California - Davis under the direction of Dr. David Segal, an internationally recognized leader in AS research. If the pre-clinical studies confirm that LB-100 reduces AS signs in rodent models, the Company has agreed to enter into discussions with FAST with respect to possible collaborations to most efficiently assess the benefit of LB-100 in patients with AS, which is a rare disease affecting an estimated one out of 12,000 to one out of 20,000 persons in the United States. The genetic cause of AS, reduced function of a specific maternal gene called Ube3, has been understood for some time, but the molecular abnormality resulting from the genetic lesion has now been shown to be increased concentrations of protein phosphatase 2A (PP2A), a molecular target of the Company’s investigational compound, LB-100. The Company has agreed to provide FAST with a supply of LB-100 to be utilized in the conduct of this study, which is initially expected to be completed within three years. Conditioned on FAST’s completion of this study, the Company has agreed to pay FAST five percent ( 5 250,000 The research team at the University of California, Davis recently completed their pre-clinical study of the potential benefit of LB-100 in a mouse model of AS, and the results are currently under review by FAST. The preliminary analysis indicates that the positive results previously reported by Chinese investigators were not confirmed in the US model. The Company is awaiting input from FAST as to whether it intends to continue to pursue pre-clinical studies of LB 100. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam (NKI), one of the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations. The Company has agreed to fund the study and provide a sufficient supply of LB-100 to conduct the study. The study is expected to take approximately two years to conduct. During the year ended December 31, 2021, the Company incurred charges in the amount of $ 55,248 Impact of the Novel Coronavirus (Covid-19) on the Company’s Business Activities The global outbreak of the novel coronavirus (Covid-19) has led to disruptions in general economic activities worldwide, as businesses and governments have taken broad actions to mitigate this public health crisis. In light of the uncertain and continually evolving situation relating to the spread of Covid-19, this pandemic could pose a risk to the Company. The extent to which the coronavirus may impact the Company’s business activities will depend on future developments, which are highly uncertain and cannot be predicted at this time. The Company intends to continue to monitor the situation and may adjust its current business plans as more information and guidance become available. The coronavirus pandemic presents a challenge to medical facilities worldwide. As the Company’s clinical trials are conducted on an outpatient basis, it is not currently possible to predict the full impact of this developing health crisis on such clinical trials, which could include delays in and increased costs of such clinical trials. Current indications from the clinical research organizations conducting the clinical trials for the Company are that such clinical trials are being delayed or extended for several months or more as a result of the coronavirus pandemic. Over the near term, there is also significant and continuing uncertainty as to the effect that the coronavirus may have on the capital markets in general and on the amount and type of financing available to the Company in particular. The Company is continuing to monitor the situation and will adjust its current business and financing plans as more information and guidance become available.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events The Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC. There were no material subsequent events which affected, or could affect, the amounts or disclosures in the consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Holdings and its wholly owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments issued for services, and the realization of deferred tax assets.
Cash	Cash Cash is primarily held in a cash bank deposit program maintained by a major financial institution. The Company’s policy is to maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the “FDIC”) and/or by the Securities Investor Protection Corporation (the “SIPC”). The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $ 250,000 500,000
Research and Development	Research and Development Research and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the acquisition, design, development and clinical trials with respect to the Company’s compounds and product candidates. Research and development costs also include the costs to produce the compounds used in research and clinical trials, which are charged to operations as incurred. Research and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are charged to operations as incurred. Obligations incurred with respect to mandatory scheduled payments under research agreements with milestone provisions are recognized as charges to research and development costs in the Company’s consolidated statement of operations based on the achievement of such milestones, as specified in the agreement. Obligations incurred with respect to mandatory scheduled payments under research agreements without milestone provisions are accounted for when due, are recognized ratably over the appropriate period, as specified in the agreement, and are recorded as liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet and are then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.
Prepaid Insurance	Prepaid Insurance Prepaid insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amortization is determined by amortizing the total policy premium charged on a straight-line basis over the respective policy periods. As the policy premiums incurred are amortizable in the ensuing twelve-month period, they are recorded as a current asset in the Company’s consolidated balance sheet at each reporting date and amortized to the Company’s consolidated statement of operations for each reporting period.
Patent and Licensing Legal and Filing Fees and Costs	Patent and Licensing Legal and Filing Fees and Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development and protection of its intellectual property are charged to operations as incurred. Patent and licensing legal and filing fees and costs were $ 729,171 553,173
Concentration of Risk	Concentration of Risk The Company periodically contracts with vendors and consultants to provide services related to the Company’s operations. Charges incurred for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred that represented 10 General and administrative costs for the years ended December 31, 2021 and 2020 include combined charges from two legal firms for general licensing and patent prosecution costs relating to the Company’s intellectual properties representing 14.6 27.1 44.2 23.5 Research and development costs for the year ended December 31, 2021 include charges from three vendors and consultants representing 30.3 21.8 14.4 65.6 13.7
Income Taxes	Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no 12 The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. The Company had not recorded any liability for uncertain tax positions as of December 31, 2021 or 2020. Subsequent to December 31, 2021, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period. The Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members contractors and consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between the vesting period and the contractual term (the “simplified method”). The estimated volatility is based on the historical volatility of the Company’s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of the common stock is determined by reference to the quoted market price of the Company’s common stock on the grant date. The expected dividend yield is based on the Company’s expectation of dividend payouts and is assumed to be zero. The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option exercises.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company’s computation of earnings (loss) per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options outstanding were anti-dilutive. At December 31, 2021 and 2020, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 December 31, 2021 2020 Series A Convertible Preferred Stock 729,167 729,167 Common stock warrants 3,110,310 3,000,000 Common stock options, including options issued in the form of warrants 2,666,667 1,475,000 Total 6,506,144 5,204,167
Fair Value of Financial Instruments	Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives and commingled investment funds and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions and enhances and simplifies various aspects of the income tax accounting guidance in ASC 740. The Company adopted ASU 2019-12 effective January 1, 2021. The adoption of ASU 2019-12 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. In August 2020, the FASB issued ASU 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon adoption of ASU 2020-06, convertible debt proceeds, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For contracts in an entity’s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company adopted ASU 2020-06 effective January 1, 2021. The adoption of ASU 2020-06 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The adoption of ASU 2021-04 is not expected to have any impact on the Company’s consolidated financial statement presentation or disclosures. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	At December 31, 2021 and 2020, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 December 31, 2021 2020 Series A Convertible Preferred Stock 729,167 729,167 Common stock warrants 3,110,310 3,000,000 Common stock options, including options issued in the form of warrants 2,666,667 1,475,000 Total 6,506,144 5,204,167

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Warrants Outstanding	A summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s public offering, during the years ended December 31, 2021 and 2020 is presented below. Schedule of Warrants Outstanding Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2019 1,500,000 $ 6.000 Issued 1,500,000 5.700 Exercised — — Expired — — Warrants outstanding at December 31, 2020 3,000,000 $ 5.850 Issued 113,310 3.700 Exercised (3,000 ) 5.700 Expired — — Warrants outstanding at December 31, 2021 3,110,310 $ 5.772 2.48 Warrants exercisable at December 31, 2020 3,000,000 $ 5.850 Warrants exercisable at December 31, 2021 3,110,310 $ 5.772 2.48
Schedule of Warrants Outstanding and Exercisable	At December 31, 2021, the outstanding warrants are exercisable at the following prices per common share: Schedule of Warrants Outstanding and Exercisable Exercise Prices Warrants Outstanding (Shares) $ 3.700 113,310 $ 5.700 1,497,000 $ 6.000 1,500,000 3,110,310

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Summary of Related Party Costs	A summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors for their services on the Board of Directors, for the years ended December 31, 2021 and 2020 is presented below. This summary includes the above-described payments to Mr. Forman in 2020 prior to his appointment as Chief Administrative Officer and excludes the payments to Mr. Weingarten in 2020 prior to his appointment as Vice President and Chief Financial Officer. Summary of Related Party Costs 2021 2020 Years Ended December 31, 2021 2020 Related party costs: Cash-based $ 822,834 $ 284,451 Stock-based 2,201,280 480,634 Total $ 3,024,114 $ 765,085

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Fair Value of Each Option Award Estimated Assumption	For stock options requiring an assessment of value during the year ended December 31, 2021, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions: Schedule of Fair Value of Each Option Award Estimated Assumption Risk-free interest rate 0.89 1.13 % Expected dividend yield 0 % Expected volatility 187.7 198.8 % Expected life 3.5 5 For stock options requiring an assessment of value during the year ended December 31, 2020, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions: Risk-free interest rate 0.23 0.31 % Expected dividend yield 0 % Expected volatility 207.7 % Expected life 4 5
Summary of Stock-based Compensation Costs	A summary of stock-based compensation costs for the years ended December 31, 2021 and 2020 is as follows: Summary of Stock-based Compensation Costs 2021 2020 Years Ended December 31, 2021 2020 Related parties $ 2,201,280 $ 480,634 Non-related parties 397,642 770,715 Total stock-based compensation costs $ 2,598,922 $ 1,251,349
Summary of Stock Option Activity Including Options Form of Warrants	A summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2021 and 2020 is presented below. Summary of Stock Option Activity Including Options Form of Warrants Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Stock options outstanding at December 31, 2019 1,308,333 $ 3.648 Granted 200,000 7.140 Exercised — — Expired (33,333 ) 3.000 Rounding adjustment attributable to reverse stock split Weighted average exercise price, reverse stock split Stock options outstanding at December 31, 2020 1,475,000 4.136 Granted 1,400,000 2.906 Exercised (208,334 ) 0.965 Expired — — Rounding adjustment attributable to reverse stock split 1 — Stock options outstanding at December 31, 2021 2,666,667 $ 3.738 3.42 Stock options exercisable at December 31, 2020 1,325,000 $ 3.796 Stock options exercisable at December 31, 2021 2,004,167 $ 3.770 3.13
Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants	The exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at December 31, 2021 are as follows: Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants Exercise Prices Options Outstanding Options Exercisable $ 0.900 33,333 33,333 $ 1.680 66,667 66,667 $ 2.060 200,000 200,000 $ 2.800 250,000 156,250 $ 3.000 666,667 666,667 $ 3.030 500,000 125,000 $ 3.200 250,000 156,250 $ 3.210 200,000 200,000 $ 6.000 166,667 166,667 $ 6.600 50,000 50,000 $ 7.140 200,000 100,000 $ 12.000 83,333 83,333 2,666,667 2,004,167

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Components of Deferred Tax Assets	Schedule of Components of Deferred Tax Assets 2021 2020 December 31, 2021 2020 Start-up and organization costs $ — $ 5,000 Research credits 451,000 390,000 Stock-based compensation 1,821,000 1,107,000 Net operating loss carryforwards 6,723,000 5,477,000 Total deferred tax assets 8,995,000 6,979,000 Valuation allowance (8,995,000 ) (6,979,000 ) Net deferred tax assets $ — $ —
Schedule of Effective Income Tax Rate	Schedule of Effective Income Tax Rate 2021 2020 Years Ended December 31, 2021 2020 U. S. federal statutory tax rate (21.0 )% (21.0 )% State income taxes, net of federal tax benefit (6.0 )% (6.0 )% Expirations related to stock-based compensation 0.6 % 0.5 % Adjustment to deferred tax asset (0.4 )% (0.8 )% Change in valuation allowance 26.8 % 27.3 % Effective tax rate 0.0 % 0.0 %

Organization and Basis of Pre_2

Organization and Basis of Presentation (Details Narrative) - USD ($)	Nov. 18, 2020	Dec. 31, 2021	Dec. 31, 2020
Cash and cash equivalents		$ 4,823,745	$ 5,069,266
Common Stock [Member]
Reverse stock split	1-for-6 reverse

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,506,144	5,204,167
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	729,167	729,167
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,110,310	3,000,000
Common Stock Options Including Options Issued in the Form of Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,666,667	1,475,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Product Information [Line Items]
Cash FDIC insurance	$ 250,000
Cash SIPC insurance	500,000
Patent and licensing costs	729,171	$ 553,173
Unrecognized tax benefits	$ 0	$ 0
Deferred setup and organization costs, amortization period	12 months
Cost of Sales [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration of risk, percentage	10.00%	10.00%
General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration of risk, percentage	14.60%	27.10%
General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member] | Stock Options Granted to Directors and Corporate Officers [Member]
Product Information [Line Items]
Concentration of risk, percentage	44.20%	23.50%
Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration of risk, percentage		13.70%
Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendors and Consultants One [Member]
Product Information [Line Items]
Concentration of risk, percentage	30.30%
Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendors and Consultants Two [Member]
Product Information [Line Items]
Concentration of risk, percentage	21.80%
Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendors and Consultants Three [Member]
Product Information [Line Items]
Concentration of risk, percentage	14.40%
Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Consultant [Member]
Product Information [Line Items]
Concentration of risk, percentage		65.60%

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - Common Stock Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares, Warrants Outstanding, Beginning Balance	3,000,000	1,500,000
Weighted Average Exercise Price, Warrants Outstanding, Beginning	$ 5.850	$ 6
Number of Shares, Issued	113,310	1,500,000
Weighted Average Exercise Price, Issued	$ 3.700	$ 5.700
Number of Shares, Exercised	(3,000)
Weighted Average Exercise Price, Exercised	$ 5.700
Number of Shares, Expired
Weighted Average Exercise Price, Expired
Number of Shares, Warrants Outstanding, Ending Balance	3,110,310	3,000,000
Weighted Average Exercise Price, Warrants Outstanding, Ending	$ 5.772	$ 5.850
Weighted Average Remaining Contractual Life (in Years), Outstanding	2 years 5 months 23 days
Number of Shares, Warrants exercisable, Ending Balance	3,110,310	3,000,000
Weighted Average Exercise Price, Warrants exercisable, Ending Balance	$ 5.772	$ 5.850
Weighted Average Remaining Contractual Life (in Years), Exercisable	2 years 5 months 23 days

Schedule of Warrants Outstand_2

Schedule of Warrants Outstanding and Exercisable (Details) - $ / shares	Dec. 31, 2021	Mar. 02, 2021
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices		$ 3.70
Warrants Outstanding Shares	3,110,310
Exercise Price One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices	$ 3.700
Warrants Outstanding Shares	113,310
Exercise Price Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices	$ 5.700
Warrants Outstanding Shares	1,497,000
Exercise Price Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices	$ 6
Warrants Outstanding Shares	1,500,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Jul. 14, 2021	Apr. 22, 2021	Mar. 02, 2021	Dec. 21, 2020	Dec. 07, 2020	Nov. 30, 2020	Jan. 21, 2016	Mar. 17, 2015	Mar. 30, 2021	Feb. 28, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Jan. 06, 2021
Class of Stock [Line Items]
Preferred stock, shares authorized											10,000,000	10,000,000
Preferred stock, par value											$ 0.0001	$ 0.0001
Common stock, shares authorized											100,000,000	100,000,000
Common stock, par value											$ 0.0001	$ 0.0001
Common stock, shares issued											13,746,593	12,402,157
Common stock, shares outstanding											13,746,593	12,402,157
Sale of stock during period, amount						$ 5,700,000
Sale of stock during period, shares						1,200,000
Equity issuance price per share						$ 4.75
Warrant exercise price per share			$ 3.70
Estimated gross proceeds from offering of shares			$ 502,717									$ 4,601,816
Warrants to purchase of common stock, shares			113,310
Common stock issuance, shares	83,333
Stock issued new issue shares			1,133,102
Share issued per share			$ 3.70
Proceeds from issuance of common stock gross			$ 4,192,478
Proceeds from issuance of common stock			$ 3,689,761								$ 3,689,761
Total cash proceeds	$ 100,000	$ 101,000
Common stock issuance		$ 125,001
Fair market value of stock														$ 2.8566
Officer and Directors [Member]
Class of Stock [Line Items]
Common stock upon the exercise of options		125,001
Officer [Member]
Class of Stock [Line Items]
Common stock upon the exercise of options		75,000
Exercise price		$ 0.72
Director One [Member]
Class of Stock [Line Items]
Common stock upon the exercise of options		16,667
Exercise price		$ 0.90
Director Two [Member]
Class of Stock [Line Items]
Common stock upon the exercise of options		33,334
Exercise price		$ 0.96
Consultant [Member]
Class of Stock [Line Items]
Common stock upon the exercise of options	83,333
Exercise price	$ 1.20
Service Agreement [Member] | I R T H Communications L L C [Member]
Class of Stock [Line Items]
Common stock, par value				$ 3.65
Stock options fully vested amount, fair value				$ 100,000
Common stock issuance, shares				27,420
Common Stock [Member]
Class of Stock [Line Items]
Stock issued new issue shares									3,000	3,000	1,133,102
Warrant [Member]
Class of Stock [Line Items]
Sale of stock during period, amount					$ 1,800
Sale of stock during period, shares					180,000
Warrant exercise price per share					$ 5.70					$ 5.70	$ 5.70		$ 5.70
Costs of public offering					$ 1,110,451
Estimated gross proceeds from offering of shares					$ 4,591,349
Stock issued new issue shares									3,000	3,000
Proceeds from warrant exercises									$ 17,100	$ 17,100
Warrant [Member] | Underwriting Agreement [Member]
Class of Stock [Line Items]
Warrants to purchase of common stock, shares					120,000
Warrant expire date					May 24, 2021
Common Stock Warrant [Member]
Class of Stock [Line Items]
Fair market value of stock											1.19
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized								350,000
Preferred stock, par value											$ 10	$ 10
Principal Cash Obligations and Commitments								175,000
Preferred stock dividend, percentage								1.00%
Annual net revenue								175,000
Preferred stock convertible into common stock							175,000				729,167	729,167
Gross proceeds from sale of transaction											$ 21,875,000
Preferred stock, shares outstanding											350,000	350,000
Preferred stock, per share redemption price								$ 50
Series A Convertible Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Preferred stock, conversion description											Each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 2.0833 shares of common stock (subject to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000.
Preferred stock convertible into common stock											2.0833
Undesignated Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized											9,650,000	9,650,000

Summary of Related Party Costs

Summary of Related Party Costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Total	$ 3,024,114	$ 765,085
Cash-Based [Member]
Related Party Transaction [Line Items]
Total	822,834	284,451
Stock-Based [Member]
Related Party Transaction [Line Items]
Total	$ 2,201,280	$ 480,634

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	May 01, 2021	Apr. 09, 2021	Aug. 12, 2020	Aug. 01, 2020	Jul. 15, 2020	Aug. 02, 2018	Dec. 31, 2021	Dec. 31, 2020
Dr. Kovach [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Compensation								$ 45,000
Eric J. Forman [Member] | General and Administrative Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Professional fees								38,000
Robert N. Weingarten [Member] | General and Administrative Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Compensation								79,995
Director [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Compensation		$ 20,000
Chairman of Audit Committee [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Compensation		10,000
Chairman of Other Committees [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Compensation		5,000
Member of Audit Committee [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Compensation		5,000
Member of Other Committees [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Compensation		$ 2,500
Independent Directors [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Compensation							$ 92,833
Consulting Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amendment description						On August 2, 2018, the Company entered into a third amendment to the consulting agreement to extend it to January 28, 2024, as well as to extend the exercise date of previously issued, fully-vested stock options for 666,667 shares of common stock, exercisable at $3.00 per share, from January 28, 2019 to January 28, 2024.
Shares of common stock issued						666,667
Exercise price per share						$ 3
Employment Agreement [Member] | Dr. Kovach [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Annual salary					$ 250,000
Compensation							250,000	62,500
Employment Agreement [Member] | Dr. James S. Miser, M.D [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Annual salary				$ 150,000
Increase in annual salary	$ 175,000
Employment Agreement [Member] | Dr. James S. Miser, M.D [Member] | General and Administrative Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Compensation							166,667	62,500
Employment Agreement [Member] | Eric J. Forman [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Annual salary			$ 120,000
Compensation							156,667	30,000
Increase in annual salary	175,000
Employment Agreement [Member] | Robert N. Weingarten [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Annual salary			$ 120,000
Compensation							$ 156,667	$ 46,451
Increase in annual salary	$ 175,000

Schedule of Fair Value of Each

Schedule of Fair Value of Each Option Award Estimated Assumption (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	0.89%	0.23%
Risk-free interest rate, maximum	1.13%	0.31%
Expected dividend yield	0.00%	0.00%
Expected volatility, minimum	187.70%
Expected volatility, maximum	198.80%
Expected volatility		207.70%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	3 years 6 months	4 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	5 years	5 years

Summary of Stock-based Compensa

Summary of Stock-based Compensation Costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Total stock-based compensation costs	$ 2,598,922	$ 1,251,349
Related Parties [Member]
Defined Benefit Plan Disclosure [Line Items]
Total stock-based compensation costs	2,201,280	480,634
Non Related Parties [Member]
Defined Benefit Plan Disclosure [Line Items]
Total stock-based compensation costs	$ 397,642	$ 770,715

Summary of Stock Option Activit

Summary of Stock Option Activity Including Options Form of Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Number of shares, stock options outstanding, at the beginning	1,475,000	1,308,333
Weighted average exercise price, stock options outstanding, at the beginning	$ 4.136	$ 3.648
Number of shares, Granted	1,400,000	200,000
Weighted average exercise price, granted	$ 2.906	$ 7.140
Number of shares, Exercised	(208,334)
Weighted average exercise price, exercised	$ 0.965
Number of shares, Expired		(33,333)
Weighted average exercise price, expired		$ 3
Number of shares, rounding adjustment attributable to reverse stock split	1
Weighted average exercise price, reverse stock split
Number of shares, stock options outstanding, at the end	2,666,667	1,475,000
Weighted average exercise price, stock options outstanding, at the end	$ 3.738	$ 4.136
Weighted average remaining contractual life (in years), stock options outstanding	3 years 5 months 1 day
Number of shares, stock options exercisable, at the end	2,004,167	1,325,000
Weighted average exercise price, stock options exercisable, at the end	$ 3.770	$ 3.796
Weighted average remaining contractual life (in years), stock options exercisable	3 years 1 month 17 days

Schedule of Exercise Prices of

Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	2,666,667
Options Exercisable (Shares)	2,004,167
Exercise Price One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 0.900
Options Outstanding (Shares)	33,333
Options Exercisable (Shares)	33,333
Exercise Price Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 1.680
Options Outstanding (Shares)	66,667
Options Exercisable (Shares)	66,667
Exercise Price Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 2.060
Options Outstanding (Shares)	200,000
Options Exercisable (Shares)	200,000
Exercise Price Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 2.800
Options Outstanding (Shares)	250,000
Options Exercisable (Shares)	156,250
Exercise Price Five [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 3
Options Outstanding (Shares)	666,667
Options Exercisable (Shares)	666,667
Exercise Price Six [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 3.030
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)	125,000
Exercise Price Seven [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 3.200
Options Outstanding (Shares)	250,000
Options Exercisable (Shares)	156,250
Exercise Price Eight [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 3.210
Options Outstanding (Shares)	200,000
Options Exercisable (Shares)	200,000
Exercise Price Nine [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 6
Options Outstanding (Shares)	166,667
Options Exercisable (Shares)	166,667
Exercise Price Ten [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 6.600
Options Outstanding (Shares)	50,000
Options Exercisable (Shares)	50,000
Exercise Price Eleven [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 7.140
Options Outstanding (Shares)	200,000
Options Exercisable (Shares)	100,000
Exercise Price Twelve [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Prices | $ / shares	$ 12
Options Outstanding (Shares)	83,333
Options Exercisable (Shares)	83,333

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)

Nov. 08, 2021

May 11, 2021

Apr. 09, 2021

Apr. 09, 2021

Jan. 06, 2021

Aug. 12, 2020

Aug. 01, 2020

Jul. 15, 2020

Jul. 14, 2020

Jul. 03, 2020

Sep. 14, 2015

Jun. 30, 2021

Dec. 31, 2021

Dec. 31, 2020

Sep. 30, 2021

Mar. 02, 2021

Sep. 14, 2017

Sep. 14, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of fully vested option exercisable

2,004,167

1,325,000

Number of warrants to purchase common stock

113,310

Warrants exercise price

$ 3.70

Number of warrants outstanding acquire common stock

3,110,310

Stock price per share

$ 2.8566

Stock option vested exercisable term

5 years

18 years

Stock options are exercisable price per share

$ 3.21

Fair value of stock options

$ 571,312

Stock based compensation

$ 2,598,922

$ 1,251,349

Total deferred compensation expense for outstanding value of unvested stock options

2,097,000

Intrinsic value of exercisable but unexercised in-the-money stock options

$ 10,000

Fair market value, per share

$ 1.19

Outstanding stock options to acquire shares of common stock not vested

662,500

Dr. Winson Sze Chun Ho [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of fully vested option issued

50,000

Dr. Yun Yen [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of fully vested option issued

50,000

Dr. Stephen Forman [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of fully vested option issued

50,000

Philip Palmedo [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of fully vested option issued

50,000

Ms.Regina Brown [Member] | General and Administrative Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock based compensation

$ 427,944

BioPharmaWorks LLC [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants exercise price

$ 2.06

Stock option vested exercisable term

5 years

Number of fully vested option issued

200,000

BioPharmaWorks LLC [Member] | General and Administrative Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock price per share

$ 1.9882

Fair value of stock options

$ 397,642

BioPharmaWorks LLC [Member] | Collaboration Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrants to purchase common stock

166,667

Number of warrants to purchase common stock per warrant

83,333.5

Warrant exercisable term

5 years

5 years

Warrants exercise price

$ 12

$ 6

Stock options fully vested amount, fair value

$ 670,715

Stock price per share

$ 4.0242

Eric J. Forman [Member] | General and Administrative Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock based compensation

100,213

138,926

Eric J. Forman [Member] | Employment Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options fully vested amount, fair value

$ 100,214

Stock price per share

$ 6.8718

Stock options description

On July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman was granted options for 58,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options have a term of five years and an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested as to 25% on August 12, 2020 and August 12, 2021, and will vest 25% on each of the second and third anniversaries of the grant date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the stock options fully-vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the years ended December 31, 2021 and 2020, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $100,213 and $138,926, respectively, with respect to these stock options.

Stock options granted to purchase common stock, issued

58,333

Stock option vested exercisable term

5 years

Stock options are exercisable price per share

$ 7.14

Fair value of stock options

$ 400,855

Dr. James Miser [Member] | General and Administrative Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock based compensation

143,163

202,782

Dr. James Miser [Member] | Employment Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options fully vested amount, fair value

$ 143,163

Stock price per share

$ 6.8718

Stock options description

Dr. James S. Miser, M.D., Dr. Miser was granted options for 83,334 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options have a term of five years and an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the effective date of the employment agreement. The options vested as to 25% on August 1, 2020 and August 1, 2021, and will vest 25% on each of the second and third anniversaries of the effective date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $572,650 ($6.8718 per share), of which $143,163 was attributable to the stock options fully-vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During the years ended December 31, 2021 and 2020, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $143,163 and $202,782, respectively, with respect to these stock options.

Stock options granted to purchase common stock, issued

83,334

Stock option vested exercisable term

5 years

Stock options are exercisable price per share

$ 7.14

Fair value of stock options

$ 572,650

Robert N. Weingarten [Member] | General and Administrative Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock based compensation

100,213

$ 138,926

Robert N. Weingarten [Member] | Employment Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options fully vested amount, fair value

$ 100,214

Stock price per share

$ 6.8718

Stock options description

On August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted options for 58,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options have a term of five years and an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested as to 25% on August 12, 2020 and August 12, 2021, and will vest 25% on each of the second and third anniversaries of the grant date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the stock options fully-vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the years ended December 31, 2021 and 2020, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $100,213 and $138,926, respectively, with respect to these stock options.

Stock options granted to purchase common stock, issued

58,333

Stock option vested exercisable term

5 years

Stock options are exercisable price per share

$ 7.14

Fair value of stock options

$ 400,855

Dr. Winson Sze Chun Ho [Member] | General and Administrative Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock based compensation

500,235

Dr. Winson Sze Chun Ho [Member] | Employment Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options fully vested amount, fair value

$ 376,800

Stock price per share

$ 3.0144

$ 3.0144

Fair value of stock options

$ 753,611

Non Officer Directors [Member] | General and Administrative Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock based compensation

$ 358,200

Non Officer Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock vesting description

Stock-based features of the compensation package consisted of the annual granting of stock options to each non-officer director to purchase 100,000 shares of common stock at the closing market price on the earlier of the date of the annual meeting of shareholders or the last business day of the month ending June 30, vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested

Number of fully vested option exercisable

100,000

100,000

500,000

Stock price per share

$ 2.84225

Stock option vested exercisable term

5 years

Stock options are exercisable price per share

$ 3.03

Fair value of stock options

$ 1,421,095

Stock options granted to purchase common stock, issued

500,000

New Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock vesting description

the granting of stock options to a new director to purchase 250,000 shares of common stock, exercisable at the closing market price on the grant date for a period of five years, vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested.

Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of fully vested option issued

200,000

Director [Member] | Ms.Regina Brown [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of fully vested option exercisable

250,000

250,000

250,000

Stock options fully vested amount, fair value

$ 329,188

Stock price per share

$ 2.6335

Stock option vested exercisable term

5 years

Stock options are exercisable price per share

$ 2.80

Fair value of stock options

$ 658,363

Director [Member] | Dr. Winson Sze Chun Ho [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of fully vested option exercisable

250,000

250,000

Stock option vested exercisable term

5 years

Stock options are exercisable price per share

$ 3.20

$ 3.20

Board of Directors Chairman [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrants outstanding acquire common stock

166,667

Warrants term, description

September 14, 2020 to September 14, 2025

Closing stock price of warrants

$ 5.40

Five Non Officer Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of fully vested option exercisable

100,000

2020 Stock Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares were available for issuance

933,333

2020 Stock Incentive Plan [Member] | Unexpired Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued

1,400,000

Shares outstanding

1,400,000

2020 Stock Incentive Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of restricted stock issued

2,333,333

Schedule of Components of Defer

Schedule of Components of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Start-up and organization costs		$ 5,000
Research credits	451,000	390,000
Stock-based compensation	1,821,000	1,107,000
Net operating loss carryforwards	6,723,000	5,477,000
Total deferred tax assets	8,995,000	6,979,000
Valuation allowance	(8,995,000)	(6,979,000)
Net deferred tax assets

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U. S. federal statutory tax rate	(21.00%)	(21.00%)
State income taxes, net of federal tax benefit	(6.00%)	(6.00%)
Expirations related to stock-based compensation	0.60%	0.50%
Adjustment to deferred tax asset	(0.40%)	(0.80%)
Change in valuation allowance	26.80%	27.30%
Effective tax rate	0.00%	0.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards amount federal	$ 23,173,000
Operating loss carryforwards amount state	$ 23,287,000
Operating loss carryforwards, expiration date	expire through 2041
Prior net operating loss conversion utilization	The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized PNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred in post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040
Prior net operating loss conversion	$ 928,313
New York State Division of Taxation and Finance [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards amount state	19,141,000
California Franchise Tax Board [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards amount state	4,146,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Tax provision	$ 0	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	May 01, 2021	Aug. 12, 2020	Sep. 12, 2018	Aug. 20, 2018	Mar. 22, 2018	Sep. 14, 2015	Dec. 24, 2013	Aug. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Loss Contingencies [Line Items]
Contractual commitment									$ 8,646,000
Research and development costs									1,736,776	$ 1,223,676
City of Hope [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									314,000
GEIS [Member]
Loss Contingencies [Line Items]
Amount related to milestone payment									67,582
NDA Consulting Corp [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee							$ 4,000		16,000	16,000
Clinical Trial Research Agreement [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment									18,443	41,142
Research and development costs									$ 104,677
Aggregate commitments expected, description									The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $601,000 as of December 31, 2021, which is expected to be incurred through December 31, 2025
Aggregate commitments expected									$ 601,000
Collaboration Agreement [Member] | GEIS [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment									24,171	43,411
Research and development costs									$ 155,053
Aggregate commitments expected, description									The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $4,250,000 as of December 31, 2021, which is expected to be incurred through December 31, 2025
Aggregate commitments expected									$ 4,250,000
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee						$ 10,000
Reimbursed expense									120,000	120,000
Development Agreement [Member]
Loss Contingencies [Line Items]
Research and development costs									$ 119,860
Aggregate commitments expected, description									The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $180,000 as of December 31, 2021, which is expected to be incurred through June 30, 2024.
Aggregate commitments expected									$ 180,000
Other Clinical Agreements [Member]
Loss Contingencies [Line Items]
Research and development costs									1,076,000
Aggregate commitments expected									318,000
Clinical Research Support Agreement [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									800,000
Clinical Research Support Agreement [Member] | City of Hope [Member]
Loss Contingencies [Line Items]
Research and development costs									378,511
Aggregate commitments expected									2,433,000
Work Order Agreement [Member]
Loss Contingencies [Line Items]
Research and development costs									91,885
Aggregate commitments expected									868,000
Work Order Agreement [Member] | City of Hope [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment									24,626
Aggregate commitments expected									24,626
Work Order Agreement [Member] | Theradex Systems, Inc. [Member]
Loss Contingencies [Line Items]
Research and development costs			$ 954,000						9,750	18,663
Material Transfer Agreement [Member] | INSERM [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									0	0
Material Transfer Agreement [Member] | INSERM [Member] | Development Milestones [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments					$ 1,750,000
Material Transfer Agreement [Member] | INSERM [Member] | Commercial Milestones [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments					$ 6,500,000
Exclusive License Agreement [Member] | First Four Years [Member]
Loss Contingencies [Line Items]
Minimum payments for royalties									50,000
Exclusive License Agreement [Member] | Five Years And Thereafter [Member]
Loss Contingencies [Line Items]
Minimum payments for royalties									100,000
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Loss Contingencies [Line Items]
Non-refundable license issue fee				$ 25,000
Annual license maintenance fee				25,000
Payments on non-refundable milestone				$ 1,897,000
Amount charges to operations									24,999	$ 25,001
Employment Agreement [Member] | Executive Officers [Member]
Loss Contingencies [Line Items]
Annual salary								$ 640,000
Agreement term								one-year period
Employment Agreement [Member] | Dr.James [Member]
Loss Contingencies [Line Items]
Annual compensation	$ 775,000
Master Service Agreement [Member] | Foundation for Angelman Syndrome Therapy [Member]
Loss Contingencies [Line Items]
Percentage of proceeds agree to pay under agreement		5.00%
Maximum amount received under agreement		$ 250,000
Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member]
Loss Contingencies [Line Items]
Research and development costs									$ 55,248